Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis

Hyun Jong Cho, Hong Yeol Yoon, Heebeom Koo, Seung Hak Ko, Jae Seong Shim, Jee Hyun Cho, Jae Hyung Park, Kwang Meyung Kim, Ick Chan Kwon, Dae Duk Kim

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe, Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACE-based nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist). Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis of cancer based on its passive and active tumor targeting strategies.

Original languageEnglish
Pages (from-to)111-118
Number of pages8
JournalJournal of Controlled Release
Volume162
Issue number1
DOIs
Publication statusPublished - 2012 Aug 20
Externally publishedYes

Fingerprint

Ceramides
Hyaluronic Acid
Magnetic Resonance Imaging
Neoplasms
Optical Imaging
Magnetic Resonance Spectroscopy
Gadolinium
Gadolinium DTPA
Particle Size
Heterografts
Contrast Media
Coloring Agents

Keywords

  • Dual modality
  • Hyaluronic acid-ceramide
  • MRI
  • NIRF
  • Tumor targeting

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Cho, H. J., Yoon, H. Y., Koo, H., Ko, S. H., Shim, J. S., Cho, J. H., ... Kim, D. D. (2012). Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis. Journal of Controlled Release, 162(1), 111-118. https://doi.org/10.1016/j.jconrel.2012.06.011

Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis. / Cho, Hyun Jong; Yoon, Hong Yeol; Koo, Heebeom; Ko, Seung Hak; Shim, Jae Seong; Cho, Jee Hyun; Park, Jae Hyung; Kim, Kwang Meyung; Kwon, Ick Chan; Kim, Dae Duk.

In: Journal of Controlled Release, Vol. 162, No. 1, 20.08.2012, p. 111-118.

Research output: Contribution to journalArticle

Cho, HJ, Yoon, HY, Koo, H, Ko, SH, Shim, JS, Cho, JH, Park, JH, Kim, KM, Kwon, IC & Kim, DD 2012, 'Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis', Journal of Controlled Release, vol. 162, no. 1, pp. 111-118. https://doi.org/10.1016/j.jconrel.2012.06.011
Cho, Hyun Jong ; Yoon, Hong Yeol ; Koo, Heebeom ; Ko, Seung Hak ; Shim, Jae Seong ; Cho, Jee Hyun ; Park, Jae Hyung ; Kim, Kwang Meyung ; Kwon, Ick Chan ; Kim, Dae Duk. / Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis. In: Journal of Controlled Release. 2012 ; Vol. 162, No. 1. pp. 111-118.
@article{0480dd4ab6264583a26134f3e8721805,
title = "Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis",
abstract = "Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe, Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACE-based nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist). Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis of cancer based on its passive and active tumor targeting strategies.",
keywords = "Dual modality, Hyaluronic acid-ceramide, MRI, NIRF, Tumor targeting",
author = "Cho, {Hyun Jong} and Yoon, {Hong Yeol} and Heebeom Koo and Ko, {Seung Hak} and Shim, {Jae Seong} and Cho, {Jee Hyun} and Park, {Jae Hyung} and Kim, {Kwang Meyung} and Kwon, {Ick Chan} and Kim, {Dae Duk}",
year = "2012",
month = "8",
day = "20",
doi = "10.1016/j.jconrel.2012.06.011",
language = "English",
volume = "162",
pages = "111--118",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis

AU - Cho, Hyun Jong

AU - Yoon, Hong Yeol

AU - Koo, Heebeom

AU - Ko, Seung Hak

AU - Shim, Jae Seong

AU - Cho, Jee Hyun

AU - Park, Jae Hyung

AU - Kim, Kwang Meyung

AU - Kwon, Ick Chan

AU - Kim, Dae Duk

PY - 2012/8/20

Y1 - 2012/8/20

N2 - Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe, Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACE-based nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist). Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis of cancer based on its passive and active tumor targeting strategies.

AB - Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe, Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACE-based nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist). Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis of cancer based on its passive and active tumor targeting strategies.

KW - Dual modality

KW - Hyaluronic acid-ceramide

KW - MRI

KW - NIRF

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=84864663396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864663396&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.06.011

DO - 10.1016/j.jconrel.2012.06.011

M3 - Article

VL - 162

SP - 111

EP - 118

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -